WO2019079618A3 - Formulations for treatment of skin conditions - Google Patents

Formulations for treatment of skin conditions Download PDF

Info

Publication number
WO2019079618A3
WO2019079618A3 PCT/US2018/056546 US2018056546W WO2019079618A3 WO 2019079618 A3 WO2019079618 A3 WO 2019079618A3 US 2018056546 W US2018056546 W US 2018056546W WO 2019079618 A3 WO2019079618 A3 WO 2019079618A3
Authority
WO
WIPO (PCT)
Prior art keywords
microbe
health
formulations
treatment
associated propionibacterium
Prior art date
Application number
PCT/US2018/056546
Other languages
French (fr)
Other versions
WO2019079618A2 (en
Inventor
Emma Taylor
David Hanzel
Daniel J. NILSON
Original Assignee
Naked Biome, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naked Biome, Inc. filed Critical Naked Biome, Inc.
Publication of WO2019079618A2 publication Critical patent/WO2019079618A2/en
Publication of WO2019079618A3 publication Critical patent/WO2019079618A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Abstract

Described herein are pharmaceutical composition comprising: a first therapeutically effective amount of a first health-associated Propionibacterium microbe; optionally, a second therapeutically effective amount of a second health-associated Propionibacterium microbe or Lactobacillus microbe; and a biological stabilizer. At least one of the first health-associated Propionibacterium microbe and second health-associated Propionibacterium microbe have a CRISPR locus in its genome comprising at least four different spacer sequences. Also described herein are methods of making and using such pharmaceutical compositions.
PCT/US2018/056546 2017-10-20 2018-10-18 Formulations for treatment of skin conditions WO2019079618A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762575316P 2017-10-20 2017-10-20
US62/575,316 2017-10-20
US201862678170P 2018-05-30 2018-05-30
US62/678,170 2018-05-30

Publications (2)

Publication Number Publication Date
WO2019079618A2 WO2019079618A2 (en) 2019-04-25
WO2019079618A3 true WO2019079618A3 (en) 2019-06-06

Family

ID=66174213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/056546 WO2019079618A2 (en) 2017-10-20 2018-10-18 Formulations for treatment of skin conditions

Country Status (1)

Country Link
WO (1) WO2019079618A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3021793A1 (en) 2016-04-21 2017-10-26 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
EP4003381A4 (en) * 2019-07-22 2024-02-28 Univ California Compositions and methods for treating skin infections and other diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361436A1 (en) * 2014-06-17 2015-12-17 Xycrobe Therapeutics, Inc. Genetically modified bacteria and methods for genetic modification of bacteria

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361436A1 (en) * 2014-06-17 2015-12-17 Xycrobe Therapeutics, Inc. Genetically modified bacteria and methods for genetic modification of bacteria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRÜGGEMANN ET AL.: "CRISPR/cas Loci of Type II Propionibacterium acnes Confer Immunity against Acquisition of Mobile Elements Present in Type I P. acnes", PLOS ONE, vol. 7, no. 3, e34171, 30 March 2012 (2012-03-30), XP055616947, DOI: 10.1371/journal.pone.0034171 *
SHU ET AL.: "Fermentation of Propionibacterium acnes, a Commensal Bacterium in the Human Skin Microbiome, as Skin Probiotics against Methicillin-Resistant Staphylococcus aureus", PLOS ONE, vol. 8, no. 2, e55380, 6 February 2013 (2013-02-06), pages e55380, XP055356917, DOI: 10.1371/journal.pone.0055380 *

Also Published As

Publication number Publication date
WO2019079618A2 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
WO2018229236A3 (en) Compositions comprising bacterial strains
WO2016170348A3 (en) Sarna compositions and methods of use
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2019004611A (en) Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains.
WO2017191274A3 (en) Rna encoding a therapeutic protein
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2023006541A (en) Fixed dose formulations.
MX2022001291A (en) Stereochemically enriched compositions for delivery of nucleic acids.
WO2017218974A3 (en) Treatment of amd using aav2 variant with aflibercept
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
MX2017015879A (en) Hydroxypropyl beta-cyclodextrin compositions and methods.
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
EP3980050A4 (en) <smallcaps/>? ? ?s. pneumoniae? ? ? ? ?methods of treating patients with an immunogenic composition that protects againstserotype 29
EP4003401A4 (en) Compositions and methods comprising protease-activated therapeutic agents
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
PH12021550611A1 (en) Interleukin 10 Conjugates and Uses Thereof
EP3965772A4 (en) Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
EP3492096A4 (en) Pharmaceutical composition for treating ocular diseases, containing cas9 protein and guide rna
EA202192815A1 (en) AAV-VECTOR-MEDIATED LARGE MUTATION HOTSPOINT DELETION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
EP3969597A4 (en) Compositions and methods for the treatment of atpase-mediated diseases
MX2021005421A (en) C11-cyclic substituted 13-membered macrolides and uses thereof.
EP4219715A3 (en) Stabilized cebpa sarna compositions and methods of use
WO2019079618A3 (en) Formulations for treatment of skin conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18867960

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18/09/2020)

122 Ep: pct application non-entry in european phase

Ref document number: 18867960

Country of ref document: EP

Kind code of ref document: A2